Trial · NCT03803124
Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD
NCT03803124, Phase 3, Completed, Regional Hospital Holstebro
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD. Trials, record NCT03803124. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03803124
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD
- NCT number
- NCT03803124
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 20 participants, actual
- Lead sponsor
- Regional Hospital Holstebro
- Conditions
- Polycystic Kidney, Autosomal Dominant
- Interventions
- Tolvaptan, Placebo
- First posted
- 2019-01-14
- Last updated
- 2019-01-14
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Renal plasma flow (RPF) | Two hours after trial medicine intake | Estimated by posterior Technetium-99m diethylenetriamine penta-acetic acid (99-mTc-DTPA) renography 2 hours after trial medicine intake. (unit of measurement= ml/min) |
| Secondary | Central and brachial blood pressures (BP) | Measured every 15 minutes during the examination day | Measured using Mobil-O-Graph® PWA (unit of measurement= mmHg) |
| Secondary | Glomerular filtration rate (GFR) | Two hours after trial medicine intake | Estimated by posterior Technetium-99m diethylenetriamine penta-acetic acid (99-mTc-DTPA) renography 2 hours after trial medicine intake. (unit of measurement= ml/min) |
| Secondary | Filtration fraction (FF) | Two hours after trial medicine intake | Estimated by posterior Technetium-99m diethylenetriamine penta-acetic acid (99-mTc-DTPA) renography 2 hours after trial medicine intake. (unit of measurement= %) |
| Secondary | Plasma concentration of vasopressin (p-AVP) | Measured before and 3 hours after trial medicine intake | Blood samples (unit of measurement= pg/ml) |
| Secondary | Plasma concentration of aldosterone (p-Aldo) | Measured before and 3 hours after trial medicine intake | Blood samples (unit of measurement= pmol/ml) |
| Secondary | Plasma concentration of angiotensin II (p-AngII) | Measured before and 3 hours after trial medicine intake | Blood samples (unit of measurement= pg/ml) |
| Secondary | Plasma concentration of renin (PRC) | Measured before and 3 hours after trial medicine intake | Blood samples (unit of measurement= pg/ml) |
| Secondary | Urine excretion of aquaporin 2 (u-AQP2) | Measured before and 3 hours after trial medicine intake | Urine sample (unit of measurement= ng/ml) |
| Secondary | Urine output (OU) | Measured before and 3 hours after trial medicine intake | Urine sample (unit of measurement= ml/min) |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03803124
GET https://conductscience.org/api/trials/v1/NCT03803124/registered